News

Press Releases
Back to Press Releases >
BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report
07/29/2013
BioRestorative Therapies
BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Jul 25, 2013) - "Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail, they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc. (OTCQB: BRTX), describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.

The Life Sciences Report: Mark, what disease indication are you exactly going after for patients suffering with back pain?

Mark Weinreb: We have developed a novel cellular therapy and therapeutic delivery device for the treatment of bulging and herniated disc disease. We believe we can effectively and safely treat patients using a nonsurgical, minimally invasive procedure that can be performed routinely in a physician's office. This technology could effectively bridge the gap between noninvasive and surgical back procedures. There are at least one million people, annually, in the U.S. who could benefit from this type of procedure with the promise of avoiding surgery. We elected to pursue this market because of the early success we have seen in several patients who have received this treatment.
TLSR: Can you very briefly describe the technology?"

Continue reading this interview with Mark Weinreb: "BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging and Herniated Disc Disease."
Read more about cell therapy and BioRestorative Therapies Inc. in The Life Sciences Report's in-depth interview with Jason Kolbert of Maxim Group: "Is Cell Therapy the 'Future of Medicine'?"
About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contact:
Adam Holdsworth

ProActive Capital
646.862.4607
adamh@proactivecapital.com

Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com

BioRestorative Therapies: A Stem Cell Biotechnology Company